Rebecca Garris

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

33h-index4.9kcitations198works4.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(180), Chronic Lymphocytic Leukemia Research(116), Chronic Myeloid Leukemia Treatments(115), Lymphoma Diagnosis and Treatment(37), CAR-T cell therapy research(20)

Publications198 total

Impact of <i>TP53</i> mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia
Blood·2025
A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL
Blood·2025
Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.
Blood·2025Open Access
A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes
Blood·2025· 1 cited
Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia
Blood·2025· 1 citedOpen Access
Protein expression signatures reveal age-specific risk patterns in B-ALL
Blood·2025Open Access
Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia
Blood·2025Open Access
Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Blood·2025· 1 citedOpen Access
Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia
Blood·2025Open Access
Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring
Blood·2025Open Access
POSTER: ALL-830 Prognostic Impact of Early NGS MRD Dynamics and Cytomolecular Risk in Newly Diagnosed Philadelphia Chromosome-Negative B-Cell ALL
Clinical Lymphoma Myeloma & Leukemia·2025
ALL-830: Prognostic Impact of Early NGS MRD Dynamics and Cytomolecular Risk in Newly Diagnosed Philadelphia Chromosome-Negative B-Cell ALL
Clinical Lymphoma Myeloma & Leukemia·2025
Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia
Blood Advances·2025Open Access
Impact of <i>TP53</i> mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia.
Journal of Clinical Oncology·2025
Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia
Cancer·2025· 10 cited
A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Blood·2024
Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
Blood·2024· 1 cited
Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
Blood·2024· 7 citedOpen Access
Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Blood·2024· 3 citedOpen Access
Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
Blood·2024· 1 cited
page 1 of 10Next →

Frequent Co-authors

Farhad Ravandi(49), Hagop M. Kantarjian(48), Guillermo Garcia‐Manero(43), Elias Jabbour(41), Nitin Jain(35), Marina Konopleva(34), Nicholas J. Short(33), Jörge E. Cortes(32), Susan O’Brien(31), Tapan M. Kadia(28), Koji Sasaki(26), Jeffrey L. Jorgensen(21), William G. Wierda(19), Deborah A. Thomas(19), Xuelin Huang(18), Naval Daver(17), Joseph D. Khoury(17), Partow Kebriaei(16), Naveen Pemmaraju(16), Gautam Borthakur(12)